Wavelength-Pharmaceuticals-Insert
X

Find Novel Oncology Drugs in Clinical Development

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): IDE196,Binimetinib

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Ideaya Biosciences

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration March 18, 2020

            Details:

            IDEAYA and Pfizer will form a Joint Development Committee (JDC), and there will be joint decision making and data sharing of the clinical trial results between the parties.

            Wuxi Shuangliang Biotechnology

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Olinvacimab,C-005

            Therapeutic Area: Oncology Product Name: TTAC-0001

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: PharmAbcine

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration August 03, 2020

            Details:

            Collaboration aims to evaluate the combination of each party's clinical candidate, olinvacimab and C-005, in treating non-small cell lung cancer (NSCLC). NSCLC is the leading cause of cancer-related deaths in the US and China.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SD-101

            Therapeutic Area: Oncology Product Name: SD-101

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: TriSalus Life Sciences

            Deal Size: $259.0 million Upfront Cash: $5.0 million

            Deal Type: Agreement August 03, 2020

            Details:

            Companies have entered into an asset purchase agreement under which TriSalus has purchased SD-101, a proprietary investigational, second-generation, Toll-like receptor 9 (TLR9) agonist CpG-C class oligodeoxynucleotide.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Antibody-drug conjugates

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: ADC Therapeutics

            Deal Size: $54.0 million Upfront Cash: Undisclosed

            Deal Type: Collaboration July 23, 2020

            Details:

            Under the expanded collaboration, ADC Therapeutics has been granted non-exclusive rights for two additional programs, which brings the total number of programs using Synaffix’ ADC technologies to five.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Foralumab,CAR-T Therapy

            Therapeutic Area: Oncology Product Name: TZLS-401

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 16, 2020

            Details:

            Tiziana has submitted a patent application on potential use of Foralumab, a fully human anti-CD3 monoclonal antibody (mAb), to improve success of CAR-T therapy for cancer and other human diseases.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CAR-T cell therapy

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Orgenesis

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration July 14, 2020

            Details:

            The agreement is part of the Orgenesis strategy of growing and expanding the POCare Network. The first collaboration under the agreement will focus on the clinical development of CAR-T and whole cell-based vaccine platform for use in cancer immunotherapies.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Methotrexate

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 07, 2020

            Details:

            The research highlights a Methotrexate-loaded microvesicles tumor therapy for cholangiocarcinoma, approved for clinical use has shown significant efficacy and safety in the treatment of cholangiocarcinoma.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): DNA plasmids

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Ziopharm Oncology

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement June 26, 2020

            Details:

            Ziopharm, based on their analyses of patient tumors, will identify TCRs on a patient-by-patient basis as well as assemble TCRs in a library for use in clinical trials. The company will use Aldevron’s neoGMP service to manufacture multiple DNA plasmids in an expedient.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): TCR based Natural Killer cells

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Lion TCR

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration June 24, 2020

            Details:

            The collaboration will initially focus on the development of TCR-NK products targeting Hepatitis B Virus (HBV) which is a leading cause of liver cancer and has a high unmet need for efficient treatment options.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): LNS8801,Pembrolizumab

            Therapeutic Area: Oncology Product Name: LNS8801

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Linnaeus Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration June 23, 2020

            Details:

            Collaboration agreement aims to study the combination of Linnaeus's lead investigational drug candidate LNS8801, and Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in patients with selected advanced solid tumors.

            PharmaCompass